BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33279970)

  • 21. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
    Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
    Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure.
    Chen C; Qu X; Gao Z; Zheng G; Wang Y; Chen X; Li H; Huang W; Zhou H
    Int Heart J; 2018 Jan; 59(1):58-63. PubMed ID: 29279523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
    Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
    Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
    Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
    Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
    Kuronuma K; Okumura Y; Morikawa T; Yokoyama K; Matsumoto N; Tachibana E; Oiwa K; Matsumoto M; Kojima T; Haruta H; Nomoto K; Sonoda K; Arima K; Kogawa R; Takahashi F; Kotani T; Ohkubo K; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Int Heart J; 2020 May; 61(3):492-502. PubMed ID: 32418966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional Handling and Prognostic Performance of Circulating Insulin-Like Growth Factor Binding Protein-7 in Heart Failure.
    Tan ESJ; Chan SP; Choi YC; Pemberton CJ; Troughton R; Poppe K; Lund M; Devlin G; Doughty RN; Richards AM
    JACC Heart Fail; 2023 Jun; 11(6):662-674. PubMed ID: 37286261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.
    Chua W; Law JP; Cardoso VR; Purmah Y; Neculau G; Jawad-Ul-Qamar M; Russell K; Turner A; Tull SP; Nehaj F; Brady P; Kastner P; Ziegler A; Gkoutos GV; Pavlovic D; Ferro CJ; Kirchhof P; Fabritz L
    PLoS Med; 2021 Feb; 18(2):e1003405. PubMed ID: 33534825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
    Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
    Latini R; Masson S; Pirelli S; Barlera S; Pulitano G; Carbonieri E; Gulizia M; Vago T; Favero C; Zdunek D; Struck J; Staszewsky L; Maggioni AP; Franzosi MG; Disertori M;
    J Intern Med; 2011 Feb; 269(2):160-71. PubMed ID: 20964739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.
    Patel RB; Vaduganathan M; Rikhi A; Chakraborty H; Greene SJ; Hernandez AF; Felker GM; Redfield MM; Butler J; Shah SJ
    JACC Heart Fail; 2019 Jan; 7(1):47-55. PubMed ID: 30409707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation.
    Fu S; Jiao J; Guo Y; Zhu B; Luo L
    BMC Geriatr; 2019 Feb; 19(1):56. PubMed ID: 30819103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death.
    Schrage B; Geelhoed B; Niiranen TJ; Gianfagna F; Vishram-Nielsen JKK; Costanzo S; Söderberg S; Ojeda FM; Vartiainen E; Donati MB; Magnussen C; Di Castelnuovo A; Camen S; Kontto J; Koenig W; Blankenberg S; de Gaetano G; Linneberg A; Jørgensen T; Zeller T; Kuulasmaa K; Tunstall-Pedoe H; Hughes M; Iacoviello L; Salomaa V; Schnabel RB
    J Am Heart Assoc; 2020 May; 9(9):e015218. PubMed ID: 32351154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Not Available].
    Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
    Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation.
    Benz AP; Aeschbacher S; Krisai P; Moschovitis G; Blum S; Meyre P; Blum MR; Rodondi N; Di Valentino M; Kobza R; De Perna ML; Bonati LH; Beer JH; Kühne M; Osswald S; Conen D;
    J Am Heart Assoc; 2021 Apr; 10(8):e019168. PubMed ID: 33843247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.